BRAF and Hypertension: The combination of BRAF and MEK inhibitors was associated with a more than 3-fold increase in risk of a decrease in LVEF and a 1.4-fold increase in risk of arterial hypertension (LVEF: RR, 3.72; 95% CI, 1.74-7.95; P < .001; I2 = 50%; arterial hypertension: RR, 1.49; 95% CI, 1.12-1.98; P = .005; I2 = 47%) (Figure 3).